INDP — Indaptus Therapeutics Income Statement
0.000.00%
- $18.19m
- $8.45m
- 10
- 17
- 69
- 23
Annual income statement for Indaptus Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 47.1 | 13.8 | 7.73 | 14.9 | 16.4 |
Operating Profit | -47.1 | -13.8 | -7.73 | -14.9 | -16.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -47 | -14 | -7.71 | -14.3 | -15.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -47.6 | -14.1 | -7.71 | -14.3 | -15.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -47.6 | -14.1 | -7.71 | -14.3 | -15.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -47.6 | -14.1 | -7.71 | -14.3 | -15.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -91.7 | -16.3 | -1.89 | -1.73 | -1.84 |